Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Article Abstract:

A mechanism for indoleamine 2,3-dioxygenase (IDO) elevation in cancer is identified to show how the pharmacological inhibitors of IDO could be used in combination with cytotoxic chemotherapeutic agents to elicit regression of established tumors. The analysis suggest that cancer suppression gene Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors might improve responses to cancer chemotherapy.

United States, Immune response, Cancer regression, Immune response regulation

---

From obscurity to the clinic

Article Abstract:

Epigenetic changes that could occur to both oncogenes and tumour suppressors are studied as diagnostics and therapeutic targets for cancer. It is found that cancer is caused by activation of oncogenes and implies that altered DNA methylation could underlie oncogene activation, thus DNA methylation inhibitors are now approved for clinical use although it is debated whether they work by reactivating tumour suppressors.

Oncogenes, Methylation

---

Similar abstracts:

• Abstracts: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. New approaches to antidepressant drug discovery: beyond monoamines
• Abstracts: Options increase in mental health. Psychological issues surrounding paternal perinatal mental health. Anxiety management for patients with symptoms of MI
• Abstracts: Muscle physiology: Part 4: Movement and muscle problems. Hearing and balance: Part 2 - The inner ear and brain
• Abstracts: Where have all the antibiotic patents gone? Uninformed consent?
• Abstracts: A brief history of [T.sub.H]17, the first major revision in the [T.sub.H]1/[T.sub.H]2 hypothesis of T cell-mediated tissue damage

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.